Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAW039 add-on therapy for uncontrolled severe eosinophilic asthma
NL-OMON53380Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in asthma, severe asthma and eosinophilic asthma (EA) (3 arms), sponsored by Novartis. Primary endpoint: Annualized rate of moderate-to-severe asthma exacerbations. Started Mar 2016; status: recruiting.
02
Drugs
fevipiprant
03
Conditions
asthmasevere asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON53380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53380.